CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
etanerceptdrug
Likely dose
etanercept 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01971346
NCT01971346Phase 4Completed
CompareCT.gov

The Immunological Basis for Treatment Resistance to Anti-TNF Treatments

University of Michigan·interventional·Posted Oct 29, 2013·Updated Mar 4, 2020

In Brief

A Phase 4 clinical trial evaluating etanercept for Psoriasis. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the relationship between two types of cell signals, type I interferon (IFN) and tumor necrosis factor (TNF), in psoriatic skin prior to and during treatment with etanercept and correlate that information with the degree of the improvement in the psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
CollaboratorsAmgen

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 29, 2013
Enrollment StartMar 13, 2014
Primary CompletionNov 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 12.7 years ago

Interventions

etanerceptdrug

100 mg Etanercept injections per week (2 separate single-use pre-filled 50 mg subcutaneous injections taken on two separate days) for 3 months